| 2019 |
| 03/01 | 12:00 行使価額修正条項付き第16回新株予約権(第三者割当て)の月間行使状況に関するお知らせ |
| 02/26 | 442 | 480 | 437 | 440 | -0.23% | 1,921,500 | 205億953万 | +15.79% |
| 02/25 | 422 | 445 | 415 | 441 | +5.5% | 768,600 | 205億5614万 | +16.67% |
| 02/22 | 437 | 438 | 416 | 418 | -5% | 706,200 | 194億8406万 | +11.17% |
| 02/21 | 419 | 441 | 416 | 440 | +6.54% | 883,900 | 205億953万 | +17.33% |
| 02/20 | 415 | 418 | 408 | 413 | +0.73% | 285,900 | 192億5099万 | +10.72% |
| 02/19 | 416 | 423 | 410 | 410 | -1.44% | 454,600 | 191億1115万 | +9.92% |
| 02/18 | 409 | 424 | 408 | 416 | +5.58% | 881,500 | 193億9083万 | +11.83% |
| 02/15 | 401 | 412 | 389 | 394 | -1.75% | 673,100 | 183億6535万 | +6.2% |
| 02/14 | 379 | 410 | 377 | 401 | +6.37% | 1,101,800 | 186億9164万 | +7.8% |
| 02/13 | 15:00 営業外収益(為替差益)の計上に関するお知らせ |
| 02/13 | 15:00 平成31年3月期第3四半期決算短信〔日本基準〕(非連結) |
| 02/13 | 372 | 383 | 364 | 377 | +2.72% | 449,500 | 175億7294万 | +1.62% |
| 02/12 | 356 | 367 | 354 | 367 | +4.26% | 245,700 | 171億681万 | -0.81% |
| 02/08 | 365 | 366 | 350 | 352 | -4.86% | 355,800 | 164億762万 | -4.86% |
| 02/07 | 381 | 384 | 366 | 370 | -4.39% | 569,100 | 172億4665万 | +0.27% |
| 02/06 | 355 | 396 | 353 | 387 | +9.32% | 1,570,200 | 180億3907万 | +5.45% |
| 02/05 | 358 | 368 | 353 | 354 | +0.57% | 425,300 | 165億85万 | -2.48% |
| 02/04 | 332 | 364 | 331 | 352 | +7.98% | 623,000 | 164億762万 | -2.22% |
| 02/01 | 15:00 行使価額修正条項付き第16回新株予約権(第三者割当て)の月間行使状況に関するお知らせ |
| 02/01 | 330 | 331 | 323 | 326 | -0.61% | 226,800 | 151億9570万 | -8.94% |
| 01/31 | 12:00 VB-111を用いた米国における臨床開発についてVBL社が開発計画を発表 |
| 01/31 | 318 | 334 | 318 | 328 | +3.8% | 417,500 | 152億8892万 | -8.38% |
| 01/30 | 328 | 330 | 314 | 316 | -9.46% | 840,400 | 147億2957万 | -11.98% |
| 01/29 | 360 | 361 | 345 | 349 | -2.51% | 464,600 | 162億6779万 | -3.06% |
| 01/28 | 371 | 371 | 358 | 358 | -2.72% | 223,800 | 166億8730万 | -0.56% |
| 01/25 | 371 | 374 | 368 | 368 | -0.27% | 187,400 | 171億5343万 | +1.94% |
| 01/24 | 371 | 373 | 365 | 369 | -0.54% | 298,200 | 172億4万 | +1.93% |
| 01/23 | 374 | 378 | 370 | 371 | -2.11% | 293,700 | 172億9326万 | +2.2% |
| 01/22 | 385 | 394 | 377 | 379 | -3.32% | 384,500 | 176億6616万 | +4.7% |
| 01/21 | 405 | 410 | 391 | 392 | -2.73% | 426,600 | 182億7213万 | +8.29% |
| 01/18 | 391 | 408 | 391 | 403 | +3.6% | 514,800 | 187億8487万 | +11.33% |
| 01/17 | 389 | 396 | 386 | 389 | -1.02% | 480,400 | 181億3229万 | +7.76% |
| 01/16 | 395 | 398 | 387 | 393 | -0.51% | 426,100 | 183億1874万 | +8.56% |
| 01/15 | 391 | 402 | 381 | 395 | -0.25% | 621,900 | 184億1197万 | +9.12% |
| 01/11 | 407 | 412 | 394 | 396 | -0.75% | 792,000 | 184億5858万 | +9.09% |
| 01/10 | 395 | 414 | 391 | 399 | +0.5% | 675,600 | 185億9842万 | +9.62% |
| 01/09 | 11:30 NC-6004と免疫チェックポイント阻害剤キイトルーダの併用による第II相臨床試験に関する新薬治験許可申請(欧州)のお知らせ |
| 01/09 | 403 | 426 | 382 | 397 | +2.06% | 1,956,500 | 185億519万 | +9.07% |
| 01/08 | 361 | 404 | 361 | 389 | +8.66% | 1,014,500 | 181億3229万 | +6.58% |
| 01/07 | 16:00 行使価額修正条項付き第16回新株予約権(第三者割当て)の月間行使状況に関するお知らせ |
| 01/07 | 370 | 374 | 354 | 358 | +1.99% | 583,100 | 166億8730万 | -1.92% |
| 01/04 | 311 | 351 | 311 | 351 | +7.67% | 502,400 | 163億6101万 | -4.36% |
| 2018 |
| 12/28 | 318 | 327 | 315 | 326 | +1.88% | 333,800 | 151億9570万 | -11.41% |
| 12/27 | 304 | 322 | 301 | 320 | +8.11% | 692,700 | 149億1602万 | -13.75% |
| 12/26 | 291 | 297 | 286 | 296 | +3.86% | 655,400 | 137億9732万 | -20.86% |
| 12/25 | 281 | 295 | 281 | 285 | -7.77% | 910,300 | 132億8458万 | -24.6% |
| 12/21 | 312 | 320 | 305 | 309 | -2.83% | 752,500 | 144億328万 | -19.32% |
| 12/20 | 340 | 343 | 316 | 318 | -7.83% | 614,500 | 148億2280万 | -17.83% |
| 12/19 | 343 | 350 | 340 | 345 | +1.47% | 318,300 | 160億8134万 | -11.54% |
| 12/18 | 350 | 351 | 340 | 340 | -5.03% | 479,800 | 158億4827万 | -13.27% |
| 12/17 | 377 | 378 | 358 | 358 | -6.04% | 556,300 | 166億8730万 | -9.37% |
| 12/14 | 392 | 399 | 377 | 381 | -2.31% | 657,900 | 177億5939万 | -4.03% |
| 12/13 | 13:20 国内第III相臨床試験に関する新規治験計画届出のお知らせ |
| 12/13 | 384 | 433 | 381 | 390 | +1.56% | 2,693,200 | 181億7890万 | -2.01% |
| 12/12 | 385 | 407 | 378 | 384 | +6.37% | 2,195,700 | 178億9923万 | -3.76% |
| 12/12 | 8:50 米国第I相パート臨床試験の主要評価項目達成のお知らせ |
| 12/11 | 373 | 377 | 360 | 361 | -1.9% | 391,400 | 168億2714万 | -9.75% |
| 12/10 | 384 | 384 | 368 | 368 | -4.91% | 478,700 | 171億5343万 | -8.68% |
| 12/07 | 392 | 396 | 387 | 387 | -0.77% | 402,500 | 180億3907万 | -4.21% |
| 12/06 | 405 | 405 | 390 | 390 | -3.23% | 493,000 | 181億7890万 | -3.7% |
| 12/05 | 400 | 411 | 396 | 403 | -0.25% | 418,800 | 187億8487万 | -0.74% |
| 12/04 | 420 | 425 | 400 | 404 | -3.12% | 550,800 | 188億3148万 | -0.49% |
| 12/03 | 15:00 行使価額修正条項付き第16回新株予約権(第三者割当て)の月間行使状況に関するお知らせ |
| 12/03 | 416 | 424 | 414 | 417 | +0.97% | 360,900 | 194億3744万 | +2.71% |
| 11/30 | 415 | 423 | 409 | 413 | -0.48% | 304,400 | 192億5099万 | +1.98% |
| 11/29 | 413 | 416 | 409 | 415 | +1.72% | 342,400 | 193億4422万 | +2.47% |
| 11/28 | 401 | 410 | 400 | 408 | +1.75% | 305,600 | 190億1793万 | +0.25% |
| 11/27 | 399 | 407 | 398 | 401 | +0.25% | 275,300 | 186億9164万 | -1.96% |
| 11/26 | 392 | 404 | 389 | 400 | +2.3% | 404,900 | 186億4503万 | -2.68% |
| 11/22 | 389 | 394 | 388 | 391 | 0% | 259,200 | 182億2552万 | -5.56% |
| 11/21 | 391 | 401 | 390 | 391 | -1.51% | 332,200 | 181億3480万 | -6.46% |
| 11/20 | 402 | 406 | 397 | 397 | -2.22% | 277,200 | 184億1309万 | -5.92% |
| 11/19 | 398 | 410 | 397 | 406 | +1.75% | 350,100 | 188億3051万 | -4.47% |
| 11/16 | 399 | 409 | 397 | 399 | -0.75% | 291,100 | 185億585万 | -6.78% |
| 11/15 | 395 | 406 | 391 | 402 | +1.26% | 304,900 | 186億4499万 | -6.73% |
| 11/14 | 401 | 404 | 394 | 397 | -0.75% | 325,500 | 184億1309万 | -8.53% |
| 11/13 | 398 | 404 | 392 | 400 | -0.99% | 468,700 | 185億5223万 | -8.47% |
| 11/12 | 422 | 422 | 403 | 404 | -2.88% | 389,000 | 187億3775万 | -8.39% |
| 11/09 | 15:00 営業外収益(為替差益)の計上に関するお知らせ |
| 11/09 | 15:00 平成31年3月期第2四半期決算短信〔日本基準〕(非連結) |
| 11/09 | 415 | 421 | 412 | 416 | 0% | 317,800 | 192億9432万 | -6.52% |
| 11/08 | 418 | 420 | 413 | 416 | +1.22% | 270,200 | 192億9432万 | -7.35% |
| 11/07 | 406 | 416 | 400 | 411 | +0.74% | 440,900 | 190億6242万 | -9.27% |
| 11/06 | 9:45 VB-111:再発悪性神経膠芽腫に対する第III相臨床試験の成績発表について |
| 11/06 | 422 | 438 | 398 | 408 | -3.09% | 866,300 | 189億2327万 | -10.92% |
| 11/05 | 414 | 425 | 407 | 421 | +1.69% | 466,000 | 195億2622万 | -9.07% |
| 11/02 | 405 | 414 | 405 | 414 | +3.24% | 325,000 | 192億156万 | -11.35% |
| 11/01 | 15:00 行使価額修正条項付き第16回新株予約権(第三者割当て)の月間行使状況に関するお知らせ |
| 11/01 | 406 | 410 | 401 | 401 | -2.67% | 285,400 | 185億9861万 | -15.04% |
| 10/31 | 402 | 412 | 400 | 412 | +2.49% | 406,900 | 191億880万 | -13.63% |
| 10/30 | 397 | 407 | 386 | 402 | +0.75% | 478,300 | 186億4499万 | -16.42% |
| 10/29 | 402 | 413 | 397 | 399 | -1.97% | 440,200 | 185億585万 | -17.73% |
| 10/26 | 425 | 428 | 404 | 407 | -2.16% | 548,700 | 188億7689万 | -16.77% |
| 10/25 | 439 | 443 | 414 | 416 | -8.57% | 881,200 | 192億9432万 | -15.62% |
| 10/24 | 456 | 461 | 451 | 455 | 0% | 282,000 | 211億316万 | -8.27% |
| 10/23 | 462 | 465 | 453 | 455 | -1.52% | 347,800 | 211億316万 | -8.45% |
| 10/22 | 11:30 皮膚科領域での医薬品展開について |
| 10/22 | 471 | 473 | 456 | 462 | -1.91% | 510,600 | 213億4143万 | -7.41% |
| 10/19 | 484 | 486 | 470 | 471 | -3.29% | 339,700 | 217億5717万 | -5.8% |
| 10/18 | 491 | 498 | 482 | 487 | 0% | 316,500 | 224億9627万 | -2.99% |
| 10/17 | 483 | 489 | 481 | 487 | +1.46% | 274,200 | 224億9627万 | -3.37% |
| 10/16 | 473 | 483 | 468 | 480 | +1.48% | 264,800 | 221億7292万 | -4.95% |
| 10/15 | 480 | 482 | 470 | 473 | -1.25% | 235,100 | 218億4956万 | -6.71% |
| 10/12 | 463 | 479 | 461 | 479 | +2.13% | 301,100 | 221億2672万 | -6.08% |
| 10/11 | 469 | 481 | 462 | 469 | -4.29% | 602,900 | 216億6479万 | -8.4% |
| 10/10 | 491 | 496 | 485 | 490 | 0% | 275,500 | 226億3485万 | -4.85% |
| 10/09 | 500 | 501 | 488 | 490 | -2.58% | 283,300 | 226億3485万 | -5.04% |
| 10/05 | 516 | 520 | 497 | 503 | -3.64% | 431,400 | 232億3537万 | -2.9% |
| 10/04 | 11:30 NC-6004と免疫チェックポイント阻害剤キイトルーダの併用による第II相臨床試験に関する新薬治験許可申請(IND)のお知らせ |
| 10/04 | 519 | 534 | 497 | 522 | +0.19% | 925,000 | 241億1305万 | +0.38% |
| 10/03 | 528 | 534 | 520 | 521 | -2.07% | 227,600 | 240億6685万 | -0.19% |
| 10/02 | 539 | 546 | 530 | 532 | -0.56% | 446,000 | 245億7498万 | +1.53% |
| 10/01 | 15:00 行使価額修正条項付き第16回新株予約権(第三者割当て)の月間行使状況に関するお知らせ |
| 10/01 | 527 | 543 | 526 | 535 | +1.9% | 267,300 | 247億1356万 | +2.1% |
| 09/28 | 525 | 532 | 520 | 525 | +0.96% | 214,700 | 242億5163万 | +0.19% |
| 09/27 | 531 | 538 | 519 | 520 | -1.89% | 347,400 | 240億2066万 | -0.95% |
